Skip to main content
Premium Trial:

Request an Annual Quote

Memory Pharmaceuticals and Monogram Biosciences Awarded US Patents

Premium
Memory Pharmaceuticals has been awarded US Patent 7,358,057, “QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells.”
 
The inventors listed on the patent are Daguang Wang and Michael De Vivo.
 
The patent describes QM-7 or QT-6 cells comprising a heterologous mutant nicotinic α7 acetylcholine receptor and/or a nucleic acid encoding it, the abstract said. These QM-7 and QT-6 cells are useful for assays such as high-throughput assays that measure the influx of cations into a cell.
 

 
Monogram Biosciences has been awarded US Patent 7,358,052, “Catalytic amplification of multiplexed assay signals.”
 
The inventor listed on the patent is Sharat Singh.
 
Its abstract said that the patent describes methods, compositions, kits, and a system for detecting one or more analytes in a sample. A mixture comprising the sample; a first binding reagent comprising a cleavage-inducing moiety and a first binding agent specific for an analyte; and one or more electrophoretic probes, each having a second binding agent, is subjected to conditions under which binding of respective binding agents occurs. The interaction between the binding agents and the analyte brings the cleavage-inducing moiety close enough to cleave the linkage tethering an electrophoretic tag to the second binding agent, thereby releasing the tag for electrophoretic separation. Separation of different tags occurs because of their distinct electrophoretic mobilities. After separation, a signal amplification moiety on each tag is activated to generate a signal to indicate the presence of a particular analyte.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.